HER2-positive breast cancer, characterized by the amplification of the ERBB2 gene, accounts for approximately 15–20% of all breast cancer cases and is associated with aggressive tumor behavior and poor prognosis (1, 2). This evidence concerns the gene ERBB2 and neoplasm.